Definitive Contract HHSN272201700076C
Award Date
7/25/17
Potential Completion Date
7/31/18
Potential Value
$223K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Zymeron Corporation
Ultimate Awardee
Not listed
NAICS Category
541711 - Research and Development in Biotechnology
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Research Triangle Park, NC 27709, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
12
Legislative Mandate
Other Statutory Authority
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
The Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $1,272,000.00 Firm Fixed Price, Definitive Contract to Zymeron Corporation, a minority-owned, for-profit biotechnology company. The contract is for the development of "Rapid Point of Care Tests to Simultaneously Quantify Anti-TB Drugs in Blood" under the Small Business Innovation Research (SBIR) Program Phase II. This research aligns with the...
The Zymeron Corporation was awarded a $299,998 firm fixed price Small Business Innovation Research Program Phase I contract from the National Institutes of Health's National Institute of Allergy and Infectious Diseases. The contract is for the research and development of a rapid point-of-care diagnostic test for histoplasmosis. This award falls under the larger SBIR solicitation issued by NIH and CDC seeking proposals in areas including cancer immunotherapy manufacturing, opioid withdrawal...
This is a $299,988 Firm Fixed Price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Zymeron Corporation, a minority-owned small business. The contract is for the development of novel, low-cost, real-time point-of-care (POC) assays for HIV viral load monitoring, HIV drug resistance monitoring, and pharmacological adherence monitoring. This contract was awarded under the Small Business Innovation...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a Firm Fixed Price Small Business Innovation Research (SBIR) Phase I contract to Zymeron Corporation, a minority-owned biotechnology company, to develop rapid point-of-care tests to simultaneously quantify anti-tuberculosis drugs in blood. The $299,920 contract, awarded on August 26, 2019, supports research and development to advance innovative diagnostics and...
This is a $599,061 Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS). The purpose is to develop imprinted polymer resins for purifying HIV envelope vaccine candidates. The prime contractor is Zymeron Corporation, a minority-owned small business biotechnology company located in Research Triangle Park,...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a Small Business Innovation Research (SBIR) Phase I contract to Qoolabs Inc., a self-certified small disadvantaged business, to develop rapid point-of-care detection tests for serologic status of individuals for cytomegalovirus (CMV) and herpes simplex virus (HSV) infections. The $225,000.00 fixed-price contract has a period of performance through July 31, 2018,...
This federal contract was awarded by the Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases to Luna Innovations Incorporated, a small business, to develop Cytomegalovirus (CMV) Immunoglobulin G (IgG) and Immunoglobulin M (IgM) lateral flow assays required to support a large-scale CMV vaccination trial. The $1,499,994.00 award has a firm fixed price and is a Small Business Technology Transfer (STTR) Phase II contract with a...
Zymeron Corporation was awarded a $400,000 firm fixed price definitive contract by the Department of Health and Human Services' National Institutes of Health National Cancer Institute to develop user-friendly technologies and devices to create an at-home Hepatitis C virus test under the Small Business Innovation Research Program Topic 441. As a small business concern, Zymeron will conduct the research and development effort at its facilities in Research Triangle Park, North Carolina through...
This is a $1,500,000.00 Firm Fixed Price contract awarded by the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases to Nanocomposix, Inc., a small business manufacturer of engineered nanoparticles. The objective of the contract is to develop cytomegalovirus (CMV) IgG and IgM lateral flow assays required to support a large-scale CMV vaccination trial. Nanocomposix has prior experience providing lateral flow assay devices,...
This is a $1,500,000.00 Firm Fixed Price contract awarded by the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases to Zymeron Corporation, a minority-owned small business, to complete Phase II tasks for a Small Business Innovation Research (SBIR) program topic. The contract supports Zymeron's research and development of technologies focused on areas like protein degradation, antibacterials, antivirals, and drug delivery...